Table1 Clinical and neuropathological characteristics of patients with AD and normal controls
|
Case |
Gender |
Age (years) |
PMI (h) |
Braak (NFT) |
Braak (Aβ) |
|
C1 |
M |
65 |
14.4 |
0 |
0 |
|
C2 |
F |
78 |
6.5 |
1 |
A |
|
C3 |
M |
78 |
6.9 |
1 |
A |
|
C4 |
M |
82 |
13.6 |
2 |
B |
|
C5 |
F |
88 |
5.7 |
2 |
A |
|
C6 |
F |
78 |
4.3 |
1 |
A |
|
C7 |
F |
83 |
7.8 |
2 |
B |
|
C8 |
M |
72 |
8.7 |
1 |
A |
|
AD1 |
M |
85 |
7.2 |
5 |
C |
|
AD2 |
F |
76 |
5.1 |
5 |
C |
|
AD3 |
F |
80 |
5.3 |
5 |
C |
|
AD4 |
M |
73 |
3.6 |
6 |
C |
|
AD5 |
F |
95 |
4.8 |
6 |
C |
|
AD6 |
M |
88 |
5.0 |
5 |
C |
|
AD7 |
F |
86 |
4.8 |
6 |
C |
|
AD8 |
F |
72 |
3.8 |
4 |
B |
NFT: Braak’s classification of stages (0−6) of AD based on the distribution and amount of neurofibrillary tangles. Aβ: Braak’s classification of the stages (A−C) of AD based on amyloid plaques.